Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies. by Kopenhaver, Jessica et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Pharmacology and Experimental 
Therapeutics Faculty Papers 
Department of Pharmacology and Experimental 
Therapeutics 
6-23-2020 
Mobilizing Toxins for Cancer Treatment: Historical Perspectives 
and Current Strategies. 
Jessica Kopenhaver 
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1020 Locust 
Street, Philadelphia, PA 19107, United States 
Robert D Carlson 
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1020 Locust 
Street, Philadelphia, PA 19107, United States 
Adam E Snook 
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1020 Locust 
Street, Philadelphia, PA 19107, United States 
Follow this and additional works at: https://jdc.jefferson.edu/petfp 
 Part of the Medical Toxicology Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Kopenhaver, Jessica; Carlson, Robert D; and Snook, Adam E, "Mobilizing Toxins for Cancer 
Treatment: Historical Perspectives and Current Strategies." (2020). Department of 
Pharmacology and Experimental Therapeutics Faculty Papers. Paper 122. 
https://jdc.jefferson.edu/petfp/122 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Faculty Papers by an 




Mobilizing Toxins for Cancer Treatment: Historical
Perspectives and Current Strategies
Jessica Kopenhaver, Robert D. Carlson and Adam E. Snook *
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1020 Locust Street,
Philadelphia, PA 19107, USA; Jessica.Kopenhaver@jefferson.edu (J.K.); Robert.Carlson@jefferson.edu (R.D.C.)
* Correspondence: Adam.Snook@jefferson.edu; Tel.: +1-215-503-7445
Received: 15 June 2020; Accepted: 17 June 2020; Published: 23 June 2020


The level of complexity in a disease like cancer presents a number of challenges for
effective treatment development, which require significant innovation to overcome. Enthusiasm
for immunotherapies and other types of biotherapeutics has grown substantially over the past decade,
as additional insight into the interplay between tumors and the immune system has allowed for a
departure from harsher conventional systemic treatments. However, amidst these impressive advances,
these therapies may still fall short for many patients. Faced with this dilemma, more biotherapeutic
options continue to be researched as potential primary or adjuvant treatments.
For millennia, poisonous compounds have been used for medicinal purposes such as mild pain
relief or numbing during surgery. Even in the modern age, plant and animal toxin-derivatives continue
to be widely used as treatments for a variety of ailments. The anticoagulants tyrofabin and hirudin, for
example, originate from venom of the African saw-scaled viper and leech secretions, respectively [1].
Even pathogenic bacteria typically considered harmful to healthy tissue may prove to be clinically
useful as studies have shown that toxins produced by these organisms can be manipulated to target
aberrant cells in a tissue- or cell-specific manner [2–5].
In this Special Issue, we explore how toxins may be used as powerful treatments against certain
cancers. The compiled articles cover how naturally-derived poisons can be utilized for cancer
therapy on multiple levels, from interrogating cytotoxic pathways in different cell types, to exploiting
toxic derivatives for pain relief in patients suffering from radiation sickness [3,5]. The Special Issue
presented this month helps to expound upon this field of research and demonstrate the potential for its
clinical applicability.
One of the first uses of toxins as cancer treatments dates back to the early twentieth century,
most notably by William Coley, a bone surgeon who discovered that a combination of heat-killed
and systemically administered bacteria could shrink osteosarcomas [6,7]. The inception of cancer
immunotherapy can arguably be traced back to the innovation of “Coley’s Toxins,” which initiated
queries into how a patient’s immune system can be triggered to kill cancer cells [2]. Immunoediting,
a prominent idea in the field of immunotherapy [8], asserts that while the immune system is at first able
to recognize and kill portions of cancer cell populations, the cancer gradually develops mutations that
permit evasion of immune detection, allowing for tumor growth and eventual metastasis [2]. Over the
past several decades, clinical strategies to overcome stagnancy in cytotoxic T cell or NK cell responses
include utilizing immune checkpoint inhibitors, such as PD-1/PD-L1 or CTLA-4 blockade [9–12],
or direct infusion of cytokines like IFNα [13,14]. Moreover, vaccines against neoantigens [15] and
known tumor-associated antigens, could prove useful for patients with genetic predispositions to
cancer. Currently, there is a phase II clinical trial investigating the ability of a mucin 1 (MUC1) vaccine
to prevent adenoma recurrence in patients at high-risk of colorectal cancer [16]. Oncolytic virotherapy,
like the FDA-approved talimogene laherparepvec (“T-VEC”) [17,18], is yet another instance of a
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therapeutic derived from bioengineering. Remarkably, this kind of virotherapy works to reshape and
adapt the tumor microenvironment (TME) to boost immune infiltration.
The mechanism of action for such biotherapeutics must be well understood for effective
employment of the treatment, as one study considers. Shiga toxins (Stxs) produced by Escherichia coli
and Shigella dysenteriae 1 pathogenic bacteria bind to the cell surface receptor glycosphingolipid
globotriaosylceramide (Gb3) [19] and induce apoptosis by inhibiting protein synthesis [3]. Gb3 is
highly upregulated in Burkitt lymphoma (BL) cells [20], and Stx/verotoxins, VT-1 and VT-2, have been
used in several preclinical studies, albeit with little success due to abundant cytotoxicity and poor
understanding of verotoxin-induced apoptosis [21]. Detailed in one paper, treating BL cells with
VT-1/Stx1 consistently induces the endoplasmic reticulum (ER) stress response by activating ER stress
sensors, IRE1 and ATF6, as well as increasing expression of the transcription factor C/REB homologous
protein (CHOP) that normally signals for programmed cell death. The role of VT-1 in cell death is noted
to be cell-specific, and in fact may shield certain tumor cells from death instead of inducing apoptosis.
ER stress enhances VT-1-induced apoptosis through CHOP in BL2 cells, but not in Ramos cells [3].
Strikingly, VT-1-induced ER stress triggers ER-phagy that in turn restrains apoptosis in Ramos cells.
Escherichia coli protein toxin, cytotoxic necrotizing factor 1 (CNF1), acts as an effective
anti-neoplastic in glioma mouse models, reducing tumor volume and increasing survival, all while
preserving the functional properties of the surrounding neurons [22,23]. As one paper acknowledges,
therapies against glioma cells must be able to cross the blood-brain barrier (BBB), otherwise, treatment
would have to be directly injected into the brain [4]. To circumvent invasive cranial injections, CNF1
was reengineered with an N-terminal BBB-crossing tag. Not only does this BBB-CNF1 variant, referred
to as the An2-CNF1-H8 variant, show comparable activity to its wild-type (WT) counterpart, but it
is also able to be purified in native conditions. This variant also exerts cell growth arrest of U87MG
GBM cells in a similar fashion to unmodified WT-CNF1 and upregulates pro-apoptotic protein Bax
expression. Experiments performed on endothelial cells demonstrate that the An2-CNF1-H8 variant is
able to enter cells and perform its intended functions, as indicated by equivalent actin architecture
changes to that of the WT. Intravenous administration of the An2-CNF1-H8 variant upregulates
spinophilin in the mouse hippocampus, suggesting BBB bypass. Altogether, these results demonstrate
that the An2-CNF1-H8 variant is likely able to cross the BBB to induce cell death in GBM cells [4] and
may be translated to future clinical studies.
Similar to clinically-approved CD3-based bispecifics, some immunotoxins utilize antibody-like
specificity to recognize tumor antigens, while also possessing a toxic domain that releases a toxin
into the target cell following internalization [24,25]. One study explores how immunotoxin efficacy
could be improved by modulating the intracellular trafficking of the toxin [26]. The inclusion of a
furin cleavage site allows immunoconjugates derived from RNase T1 and the fungal ribotoxin α-sarcin
(scFvA33furT1 and IMTXA33furαS, respectively) to be purified with optimized properties for colorectal
tumor treatment. It is also noted that the two immunotoxins are trafficked in different pathways
after endocytosis. After binding to their target GPA33 on the surface of W1222 colorectal cancer cells,
IMTXA33furαS goes through the endosome-Golgi-apparatus network, and scFvA33furT1 appears
distributed between the lysosomes and the Golgi-apparatus. The differences in trafficking pathways
between the two immunoconjugates align with what is observed from their original constructs [27].
In vitro functional characterization of these variants demonstrates enhanced antitumor efficiency due
to increased ability to release their toxic domain into the cytosol, as well as high thermostability and
target specificity.
Aside from direct applications as cancer treatments, toxins could be used to mitigate pain directly
caused by tumor pressure, or neuropathic pain as a side effect of radiation or surgery in cancer
patients [5]. Many clinical studies [28–38] have investigated the use of botulinum neurotoxins (BoNT)
as potent systemic analgesics, as these toxins block acetylcholine release from the neuromuscular
junction or inhibit neurotransmitters at both peripheral and central sensory levels [39–42]. Additionally,
some sources claim that spiking certain cancer cell lines with BoNT slows growth and mitosis, as well
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as enhances apoptosis [43]. Studies of pain induced by radiation and/or surgery suggest that the local
injection of BoNT improves neuropathic pain and local muscle spasm in the direct vicinity of the site
of surgery and/or radiation. However, this type of pain-management therapy requires blinded and
placebo-controlled studies to confirm its efficacy [5]. The results from various studies investigating the
use of BoNT as an anti-tumor therapeutic also show promise. In several in vivo experiments, direct
injection of BoNT into various malignant tumors demonstrated cellular apoptosis and reduction of
tumor size [44–46]. Adding BoNT (Type A) to a diverse range of cancer cell cultures showed slowed
cell growth, as well as induction of apoptosis and reduction of mitotic activity [47–52].
Although some cancers have been treated with relative success in the past twenty years, there still
remains a paucity of options for patients with difficult to treat, relapsing, or rare cancers. Indeed, cancer
is surpassing cardiovascular disease to become the leading cause of death in many populations around
the world. This Special Issue presents impactful research that explores the use of toxins as feasible and
pertinent cancer therapies which some day may be the solution for so many suffering patients.
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